NCT05863260招募中不适用
Tislelizumab (Anti-PD-1) Combined With Definitive Chemoradiotherapy in Recurrent Cervical Cancer (PILOT-2020-511): a Single-arm, Phase 2 Trial
适应症
干预措施
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- ORR
研究概览
简要总结
Tislelizumab combined with chemoradiotherapy in the treatment of recurrent/ metastasis cervical cancer: a single arm,single center， phase ii and observational clinical study
详细描述
Tislelizumab combined with chemoradiotherapy in the treatment of recurrent/ metastasis cervical cancer: a single arm,single center， phase ii and observational clinical study
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •For patients with recurrent or metastatic cervical cancer after initial standard treatment (including radical surgery or radical radiotherapy), the lesions are located out of the field of previous radiotherapy, with no more than 5 recurrent or metastatic foci, and the radiotherapy is feasible according to the evaluation of radiotherapy physician; and at least 1 lesion (without previous radiotherapy) meets the target lesion standard of RECIST 1.1;
- •Cervical adenocarcinoma, squamous cell carcinoma or adenosquamous cell carcinoma confirmed by previous histology;
- •Surgical resection is not recommended for recurrent lesions, or patients choose not to accept surgery voluntarily;
- •The researchers evaluated the suitability of radiotherapy
- •ECoG 0-1; life expectancy > 6 months;
- •Aged 18-70 years;
- •No serious allergic history;
- •Hemoglobin > 100 g / L, WBC > 3.5 * 10 ^ 9 / L, neutrophils > 1.5 * 10 ^ 9 / L, platelets > 100 * 10 ^ 9 / L, Cr < 1.5 * normal upper limit, TB < 2.5 * normal upper limit, AST and Al < 2.5 * normal upper limit, AKP < 2.5 * normal upper limit;
- •Ability to sign informed consent.
排除标准
- •Histologically, small cell (neuroendocrine) cervical cancer, mucinous adenocarcinoma, carcinosarcoma and other pathological types were confirmed;
- •Primary malignant tumor with activity in other parts, except for the following:
- •Those who have been cured have no known active disease at least 5 years before the first IP administration, and the potential risk of recurrence is low;
- •Fully treat non melanoma skin cancer or malignant nevus without disease signs;
- •Fully treated carcinoma in situ, no signs of disease.
- •The recurrent lesions have received chemotherapy, radiotherapy or other anti-tumor treatment;
- •Bone metastasis;
- •Brain metastasis;
- •Pregnant or lactating patients;
- •In the past, there was abnormal thyroid function, and under the condition of drug treatment, thyroid function could not be maintained in the normal range;
- •Diagnosis of immune deficiency or treatment with chronic systemic steroids (doses more than 10 mg per day of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days before enrollment;
- •Patients with active autoimmune diseases need systemic treatment in the past 2 years;
- •A history of (noninfectious) pneumonia requiring steroids or current pneumonia;
- •There are active infections that need systematic treatment;
- •Known history of human immunodeficiency virus (HIV) infection;
- •Known history of hepatitis B or known active hepatitis C virus infection;
- •Known history of active tuberculosis (TB);
- •Uncontrolled comorbidities, including but not limited to: persistent or active infection, symptomatic congestive heart failure, uncontrolled hypertension, uncontrolled diabetes, uncontrolled arrhythmias, active interstitial lung disease (ILD), severe chronic gastrointestinal disease with diarrhea, or may limit compliance with study requirements, leading to AE Mental / social problems that significantly increase or affect the ability of subjects to provide written informed consent;
- •14 days before admission, the operation was too large and had not recovered;
- •Participate in other clinical trials at present or within 28 days before selection;
- •Any indications, including but not limited to other anti-CTLA-4, anti-PD-1, anti-PD-L1 and anti-PD-L2 antibodies or therapeutic anti-cancer vaccines, were treated by immunomediated therapy prior to the study;
- •Any synchronous chemotherapy, research drug, biological product, or hormone therapy used to treat tumors. Hormone therapy can also be used to treat non tumor related diseases (e.g., hormone replacement therapy);
- •Allogeneic tissue / solid organ transplantation was carried out.
研究组 & 干预措施
Intervention
Paclitaxel 135mg / m2d1 + cisplatin 60mg / m2d1 (cisplatin resistance or cisplatin intolerance changed to carboplatin AUC = 5d1), q3w × 4 and Standard IMRT and radiotherapyTislelizumab 200mg, IV, q3w, the day before radiotherapy
干预措施: Treatment Group (Drug)
结局指标
主要结局
ORR
时间窗: 1 year
Objective response rate
次要结局
- 1-year OS(1 year)
- 1-year PFS(1 year)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based ChemotherapyRecurrent Cervical CarcinomaPersistent Advanced Cervical CarcinomaChemotherapyAnti-PD-1 AntibodyImmunotherapyNCT04188860Lei Li34
招募中
2 期
Tislelizumab Combined With Concurrent Chemoradiotherapy as First-line Treatment for Stage IIIC2 Cervical CancerCervical CancerNCT05511623First Affiliated Hospital of Guangxi Medical University112
进行中（未招募）
2 期
Combination of Tislelizumab and Chemoradiotherapy in Esophageal Cancer (EC-CRT-002)Esophageal Squamous Cell CarcinomaLocally Advanced Esophageal Squamous Cell CarcinomaNCT05520619Sun Yat-sen University114
招募中
2 期
Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical CancerUterine Cervical NeoplasmsNCT05588219Yong Zhang,MD30
尚未招募
2 期
Tislelizumab Combined with Chemotherapy and All Trans Retinoic Acid for Locally Advanced or Metastatic Esophageal Squamous Cell CarcinomaEsophageal Squamous Cell CarcinomaNCT06703047Fudan University180